

## Special Issue

# Recent Efforts to Improve mRNA Vaccine Efficacy

### Message from the Guest Editor

Recent advancements have facilitated the design of mRNA vaccine constructs. These include the incorporation of modified nucleotides and the change in untranslated regions (UTRs), tailoring the PoyIA tail, and the development of innovative strategies that boost antigen expression and immunogenicity while minimizing adverse effects. Additionally, cutting-edge approaches are being investigated to improve tissue targeting, modify innate immune sensing, and combine mRNA vaccines with effective adjuvants or immunomodulators for broader and more durable protection. This collection will provide an overview of the current landscape and future directions for mRNA vaccines across infectious diseases, oncology, and beyond. We invite articles, reviews, or perspectives on the latest findings that highlight the following:

- Enhancements in mRNA stability;
- Strategies for improving transcriptional efficiency;
- Optimization of delivery systems;
- Novel adjuvant strategies in improving mRNA vaccines;
- Preclinical and clinical insights into improving the efficacy and durability of mRNA vaccines.

---

### Guest Editor

Dr. Srinivasa Reddy Bonam

Vaccine Immunology Laboratory, Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India

---

### Deadline for manuscript submissions

1 September 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/253378](https://mdpi.com/si/253378)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).